Novavax Receives the Tech Council of Maryland’s Chairman’s Award
May 12 2016 - 8:30AM
Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company
focused on the discovery, development and commercialization of
recombinant nanoparticle vaccines and adjuvants, today announced it
received the Tech Council of Maryland’s (TCM) Chairman’s Award. The
award was announced at the TCM Industry Award Celebration on May
11, 2016.
The Chairman's Award is presented to a member
company or individual that best exemplifies excellence in
Maryland's technology or life science industry. The Award
recognizes a company that is a pillar in the community, not only
through market success or job creation, but by consistently giving
back, getting involved and advancing the climate for
innovation.
“Novavax is the embodiment of what we look for
when selecting an honoree for the Chairman’s award. The company has
built a successful business, employing 450 people in Maryland who
are developing vaccines that positively impact global health, and
has played an important role in fostering growth of the state’s
life sciences community,” said Rene B. LaVigne, TCM chairman-elect
and president and CEO of Iron Bow Technologies. "TCM appreciates
Novavax’s significant contributions to the association, the state’s
economy and innovations in healthcare."
“I am honored to accept this award on behalf of
the entire Novavax team,” said Stanley C. Erck, President and CEO,
Novavax. “The Tech Council of Maryland facilitates a collaborative
community of technology and life science companies who aim to make
an impact in our region and beyond. We are thrilled that this award
recognizes the hard work and dedication of our more than 450
SuperNovas, our groundbreaking achievements in developing novel
vaccines and our commitment to the Maryland life science and
technology community.”
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage
vaccine company committed to delivering novel products to prevent a
broad range of infectious diseases. Our recombinant nanoparticles
and Matrix-M™ adjuvant technology are the foundation for
groundbreaking innovation that improves global health through safe
and effective vaccines. Additional information about Novavax is
available on the Company's website, novavax.com.
Contact:
Novavax, Inc.
Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Andrea N. Flynn, Ph.D.
Associate Director, Investor Relations
ir@novavax.com
240-268-2000
Russo Partners, LLC
David Schull
Todd Davenport, Ph.D.
david.schull@russopartnersllc.com
todd.davenport@russopartnersllc.com
212-845-4271
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024